News

  • 6 October 2011

    Gilead granted NCINIs rights by Boehringer

    Gilead Sciences has received exclusive worldwide rights to research, develop and commercialise Boehringer Ingelheim's novel non-catalytic site integrase inhibitors (NCINIs) for HIV.

  • 5 October 2011

    Novavax RSV vaccine Phase 1 trial shows efficacy

    A Phase I clinical study conducted by Novavax has demonstrated positive top-line results of its respiratory syncytial virus (RSV) fusion (F) recombinant nanoparticle vaccine candidate.

  • 4 October 2011

    Baxter seeks European approval for HyQ

    Baxter International has submitted an application to the European Medicines Agency's Committee for Human Medicinal Products seeking marketing authorisation for HyQ, the company's investigational immunoglobulin (IG) therapy for use in...

Go Top